Ongoing Clinical Trials, New Services, and Financial Results - Research Report on Celldex Therapeutics, Allscripts, Covance, PDL BioPharma, and BioScrip

NEW YORK, August 15, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Celldex Therapeutics, Inc. (NASDAQ: CLDX), Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX), Covance Inc. (NYSE: CVD), PDL BioPharma Inc. (NASDAQ: PDLI), and BioScrip Inc. (NASDAQ: BIOS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celldex Therapeutics, Inc. Research Report

On August 12, 2013, Celldex Therapeutics, Inc. (Celldex Therapeutics) announced that it has recently completed enrollment in an initial cohort (n=25) of Avastin (bevacizumab) refractory patients in the Company's ongoing ReACT study of rindopepimut in EGFRvIII (v3)-positive glioblastoma (GBM). Celldex Therapeutics stated that based on early evidence of anti-tumor activity, including stable disease, tumor shrinkage, and investigator-reported response, it has decided to add an expansion cohort of approximately 75 patients to better characterize the potential activity of rindopepimut in this refractory patient population. The Company also stated that enrollment in the expansion cohort has started, and it will assess rindopepimut plus Avastin like the initial cohort. Celldex Therapeutics expects to announce a formal review of the results from the initial 25 patients at the Society for Neuro-Oncology Annual Meeting in November 2013. The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b443_CLDX]

Allscripts Healthcare Solutions Inc. Research Report

On August 8, 2013, Allscripts Healthcare Solutions Inc. (Allscripts) announced its financial results for Q2 2013. The Company's total revenues declined 6.8% YoY to $344.8 million during the quarter, while bookings grew 10.3% YoY to $214.1 million. Net loss stood at $22.9 million, or $0.13 per diluted share, in Q2 2013, compared to net income of $8 million, or $0.04 per diluted share, in Q2 2012. Paul M. Black, President and Chief Executive Officer of Allscripts, said, "We will leverage our recent success, including the certification of all Meaningful Use 2014 editions of our core clinical solutions, to drive further operational momentum. In addition, successful new client activations drive increasing confidence among clients and prospects alike. Allscripts value-proposition of fostering an Open Connected Community of Health clearly distinguishes the Company in the global healthcare IT market." The Full Research Report on Allscripts Healthcare Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1787_MDRX]

Covance Inc. Research Report

On August 6, 2013, Covance Inc. (Covance) announced the creation of a new service offering that aims to provide support to the Company's biopharmaceutical and medical device clients to manage contracts in managed markets. According to the Company, its managed markets services will help clients maximize value by improving controls and management of contract terms and associated payments. Covance also stated that the new service will help biopharmaceutical and medical device clients achieve higher market share by gaining better visibility into contract performance with managed care organizations, group purchasing organizations, federal and state programs, and wholesalers. Steve Medina, Covance's Vice President, Managed Market Services, is leading the new effort.The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5691_CVD]

PDL BioPharma Inc. Research Report

On August 8, 2013, PDL BioPharma Inc. (PDL BioPharma) reported its Q2 2013 and H1 2013 financial results. The Company's total revenues increased 14.1% YoY to $143.6 million during the quarter. Net income was $93.7 million, or $0.62 per diluted share, in Q2 2013, compared to net income of $73.5 million, or $0.52 per diluted share, in Q2 2012. According to PDL BioPharma, the increase in net income in Q2 2013 was primarily due to the 14% increase in royalty revenues, and the release of a tax liability of $5.7 million which reduced the effective tax rate for the quarter. Net income for H1 2013 was $147.2 million, or $0.96 per diluted share, compared with net income of $113.7 million, or $0.80 per diluted share, in H1 2012. The Full Research Report on PDL BioPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/066b_PDLI]

BioScrip Inc. Research Report

On August 7, 2013, BioScrip Inc. (BioScrip) announced its Q2 2013 financial results. The Company's total revenue increased 22.3% YoY to $190.7 million during the quarter. Net loss was $8.9 million, or $0.14 per diluted share, in Q2 2013, compared to net income of $71.8 million, or $1.29 per diluted share, in Q2 2012. Commenting on the results, Rick Smith, President and Chief Executive Officer of BioScrip, said, "The infusion business again posted robust organic growth and reflects continued progress in the execution of our infusion-focused strategy. Our goals of expanding infusion margins and generating operating leverage are consistent with our expectations and are beginning to yield results. We remain focused on the key growth drivers of our business and our strategic plan. In the quarter, however, our results were impacted by weaker-than-expected contributions from our PBM segment." The Company expects its full-year 2013 revenue to be in the range of $830 million to $865 million and its full-year 2013 adjusted EBITDA to be in the range of $67 million to $73 million. The Full Research Report on BioScrip Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4879_BIOS]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Analysts' Corner